RocketDNA Ltd is acquiring the remaining 40% of its Western Australian subsidiary in a $1 million share-based transaction, simplifying its group structure without operational changes.
- Acquisition of remaining 40% stake in RocketDNA (WA)
- Consideration paid entirely in shares valued at $1 million
- Transaction removes non-controlling interest and simplifies structure
- Shares issued will be held in escrow for 12 months
- Founders aligned with RocketDNA shareholders post-transaction
RocketDNA Moves to Full Ownership of Key WA Subsidiary
RocketDNA Ltd (ASX:RKT) is set to consolidate its hold on RocketDNA (WA) Pty Ltd by acquiring the remaining 40% stake it does not already own. The deal values the minority interest at A$1.0 million and will be settled entirely through the issuance of new RocketDNA shares, representing roughly 3.5% of the company’s current issued capital. This transaction marks a tidy-up of the group’s ownership structure but leaves day-to-day operations and reported financials untouched.
No Operational Changes, Just Structural Simplification
RocketDNA (WA) is the group’s primary Australian revenue generator, operating mainly in Western Australia. The company initially acquired a 60% controlling interest in the subsidiary in 2021 and has since consolidated its financials accordingly. By buying out the remaining 40% from Investmin Pty Ltd, the McKern Family Trust, and the McLeay Family Trust, RocketDNA removes the non-controlling interest from its balance sheet and simplifies reporting lines. The move does not affect customers, strategy, or consolidated revenue, maintaining continuity for stakeholders.
Share-Based Consideration Aligns Founders with Shareholders
The $1 million consideration will be paid in approximately 41.8 million new shares priced at the 20-day volume weighted average price of $0.023942, with these shares subject to a 12-month voluntary escrow. This arrangement aligns the interests of the original founders, who remain active in the business, with RocketDNA’s broader shareholder base. Notably, co-founder Evan McKern, holding a senior technical role, and Shane McLeay, a director of the subsidiary, will each receive 40% of the consideration shares, reinforcing continuity in leadership and operational insight.
Completion Hinges on Standard Conditions and Loan Amendments
The acquisition is subject to customary conditions, including the absence of any material adverse change and the amendment of an intercompany loan from Entech Pty Ltd; owned by Shane McLeay; to commercial terms. The shares will be issued once these conditions are satisfied or waived within 90 days. The transaction is a separately negotiated purchase and is not linked to prior call option arrangements.
Strategic Implications for RocketDNA’s Growth
While the acquisition is primarily structural, it occurs amid a period of steady growth and operational scaling for RocketDNA. The company has recently reported increased revenue and expanded drone operations across Australia and Africa, supported by multi-year contracts with major mining clients. This consolidation could streamline decision-making and financial reporting as RocketDNA continues to develop its AI-powered drone solutions and proprietary Skylink® operating system, which has been deployed with Tier-1 mining customers.
Bottom Line?
The share-based acquisition simplifies RocketDNA’s structure and strengthens founder alignment, setting a clearer path for future operational focus and growth.
Questions in the middle?
- Will the removal of the non-controlling interest impact RocketDNA’s future capital strategies?
- How might the escrowed shares influence founder involvement and company governance over the next year?
- What are the implications of the intercompany loan amendment on RocketDNA’s financial flexibility?